Elgin Turkoz Uluer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Elgin Turkoz Uluer has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Sevinc Inan
Department of Histology and Embryology, Faculty of Medicine, İzmir University of Economics, İzmir, Turkey
3 shared publications - Cevval Ulman
Department of Biochemistry, Faculty of Medicine, Manisa Celal Bayar University, Manisa, Turkey
1 shared publication - Gulcin Ekizceli
Department of Histology and Embryology, Faculty of Medicine, Yalova University, Yalova, Türkiye image/svg+xml
1 shared publication - Gulden Diniz
Izmir Democracy University Medical School, Buca Seyfi Demirsoy Training and Research Hospital
1 shared publication - Işıl Aydemir
Department of Histology and Embryology, Faculty of Medicine, Niğde Ömer Halisdemir University, Niğde, Turkey
1 shared publication - Kemal Ozbilgin
Department of Histology and Embryology, Faculty of Medicine Manisa Celal Bayar University Manisa Türkiye
1 shared publication
Latest Publications
- 7 August 2026
- Published by Springer Nature in Journal of Molecular Histology
- Vol. 57 (4) , 262
Stage-dependent expression and nuclear localization of EZH2 in endometrial carcinogenesis: evidence from cell lines and human tissues
- 7 August 2026
- Published by Springer Nature in Journal of Molecular Histology
- Vol. 57 (4) , 262
Stage-dependent expression and nuclear localization of EZH2 in endometrial carcinogenesis: evidence from cell lines and human tissues
- Open Access
- 22 April 2026
- Published by Pera Yayıncılık Hizmetleri in European Journal of Therapeutics
The Dual Mechanistic Actions of Natural Compounds CAPE and EGCG Targeting VEGF and PI3K/Akt/mTOR Pathways in Lung Cancer
Objective: Lung cancer is characterized by uncontrolled proliferation, loss of apoptosis, angiogenesis, and metastatic potential. Caffeic acid phenethyl ester (CAPE), the major bioactive molecule of propolis, and epigallocatechin gallate (EGCG), a essential polyphenol of green tea, have documented antioxidant, anti-proliferative, and anti-angiogenic effects. This study aimed to investigate the effects of EGCG and CAPE on VEGF and the PI3K/Akt/mTOR signaling pathway, key regulators of lung cancer progression, using in silico and in vitro models. Methods: This study Lung cancer cells (DSMZ/ACC-234) was conducted to demonstrate the inhibition of cell proliferation by the MTT method, molecular binding via autodock vina and protein expression by immunohistochemistry analysis, targeting the VEGF and PI3K/Akt/mTOR pathways with CAPE and EGCG treatment. Results: EGCG and CAPE treatments significantly reduced cell proliferation in lung cancer cells. Untreated cells exhibited strong to very strong immunoreactivity for VEGF and PI3K/Akt/mTOR pathway markers, whereas EGCG reduced these signals to mild–moderate levels and to CAPE moderate–strong levels. Since both treatments resulted in a statistically significant increase in mTORC1 immunoreactivity, molecular docking targeting was performed via it. Conclusion: EGCG and CAPE exhibit significant anti-proliferative and anti-angiogenic effects by adjusting the VEGF and PI3K/Akt/mTOR signaling pathways in lung cancer cells. mTORC1 activation molecular binding affinity is higher in the CAPE-treated group compared to the EGCG group. These findings highlight the therapeutic importance of targeting these pathways in developing novel treatment strategies for lung cancer.
- 22 April 2026
- Published by Pera Yayıncılık Hizmetleri in European Journal of Therapeutics
Open AccessThe Dual Mechanistic Actions of Natural Compounds CAPE and EGCG Targeting VEGF and PI3K/Akt/mTOR Pathways in Lung Cancer
Objective: Lung cancer is characterized by uncontrolled proliferation, loss of apoptosis, angiogenesis, and metastatic potential. Caffeic acid phenethyl ester (CAPE), the major bioactive molecule of propolis, and epigallocatechin gallate (EGCG), a essential polyphenol of green tea, have documented antioxidant, anti-proliferative, and anti-angiogenic effects. This study aimed to investigate the effects of EGCG and CAPE on VEGF and the PI3K/Akt/mTOR signaling pathway, key regulators of lung cancer progression, using in silico and in vitro models. Methods: This study Lung cancer cells (DSMZ/ACC-234) was conducted to demonstrate the inhibition of cell proliferation by the MTT method, molecular binding via autodock vina and protein expression by immunohistochemistry analysis, targeting the VEGF and PI3K/Akt/mTOR pathways with CAPE and EGCG treatment. Results: EGCG and CAPE treatments significantly reduced cell proliferation in lung cancer cells. Untreated cells exhibited strong to very strong immunoreactivity for VEGF and PI3K/Akt/mTOR pathway markers, whereas EGCG reduced these signals to mild–moderate levels and to CAPE moderate–strong levels. Since both treatments resulted in a statistically significant increase in mTORC1 immunoreactivity, molecular docking targeting was performed via it. Conclusion: EGCG and CAPE exhibit significant anti-proliferative and anti-angiogenic effects by adjusting the VEGF and PI3K/Akt/mTOR signaling pathways in lung cancer cells. mTORC1 activation molecular binding affinity is higher in the CAPE-treated group compared to the EGCG group. These findings highlight the therapeutic importance of targeting these pathways in developing novel treatment strategies for lung cancer.
- 27 April 2022
- Published by Taylor & Francis in Biotechnic & Histochemistry
- Vol. 97 (8) , 593-603
Continuous and intermittent parathyroid hormone administration promotes osteogenic differentiation and activity of programmable cells of monocytic origin
Bone healing deficiencies are challenging for orthopedic practice. The use of stem cells with scaffolds to treat bone tissue losses currently is popular for promoting regeneration of tissue. Programmable cells of monocytic origin (PCMO) may differentiate into three germ layers and may be a promising alternative treatment due to their stem cell-like properties. Parathyroid hormone (PTH) participates in bone metabolism. Intermittent administration of PTH promotes osteogenic activity of mesenchymal stem cdells (MSC). We investigated the osteogenic effects of continuous and intermittent administration of PTH on PCMO. Mononuclear cells were harvested from the peripheral blood of healthy donors. Isolated cells were cultured for six days in a de-differentiation medium. Indirect immunocytochemistry using anti-CD14, anti-CD45 and anti-CD90 primary antibodies, as well as electron microscopy were used to detect PCMO. PCMO then were cultured in an osteogenic differentiation medium supplemented with continuous or intermittent 50 ng/ml PTH. The PTH-free control group (CG), intermittent PTH treated group (IPG) and continuous PTH treated group (CPG) were cultured and assessed for their differentiation into osteogenic lineage cells by indirect immunocytochemistry using anti-collagen I, anti-osteonectin and anti-osteocalcin primary antibodies. Osteoblast-like cells obtained by continuous or intermittent PTH administration exhibited increased levels of collagen I, osteonectin and osteocalcin immunoreactivity. We found that continuous and intermittent PTH administration to PCMO enhanced their differentiation to osteogenic lineage cells and increased osteoblastic activity.
- 27 April 2022
- Published by Taylor & Francis in Biotechnic & Histochemistry
- Vol. 97 (8) , 593-603
Continuous and intermittent parathyroid hormone administration promotes osteogenic differentiation and activity of programmable cells of monocytic origin
Bone healing deficiencies are challenging for orthopedic practice. The use of stem cells with scaffolds to treat bone tissue losses currently is popular for promoting regeneration of tissue. Programmable cells of monocytic origin (PCMO) may differentiate into three germ layers and may be a promising alternative treatment due to their stem cell-like properties. Parathyroid hormone (PTH) participates in bone metabolism. Intermittent administration of PTH promotes osteogenic activity of mesenchymal stem cdells (MSC). We investigated the osteogenic effects of continuous and intermittent administration of PTH on PCMO. Mononuclear cells were harvested from the peripheral blood of healthy donors. Isolated cells were cultured for six days in a de-differentiation medium. Indirect immunocytochemistry using anti-CD14, anti-CD45 and anti-CD90 primary antibodies, as well as electron microscopy were used to detect PCMO. PCMO then were cultured in an osteogenic differentiation medium supplemented with continuous or intermittent 50 ng/ml PTH. The PTH-free control group (CG), intermittent PTH treated group (IPG) and continuous PTH treated group (CPG) were cultured and assessed for their differentiation into osteogenic lineage cells by indirect immunocytochemistry using anti-collagen I, anti-osteonectin and anti-osteocalcin primary antibodies. Osteoblast-like cells obtained by continuous or intermittent PTH administration exhibited increased levels of collagen I, osteonectin and osteocalcin immunoreactivity. We found that continuous and intermittent PTH administration to PCMO enhanced their differentiation to osteogenic lineage cells and increased osteoblastic activity.